CSIMarket
 


Kempharm Inc  (KMPH)
Other Ticker:  
 

Kempharm Inc's Long Term Debt to Equity

KMPH's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth




KMPH Long Term Debt to Equity (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change -28.8 % -24.05 % 44.21 % - -
Y / Y Long Term Debt Change - - - - -
Long Term Debt to Equity MRQ 0.14 0.13 - - -
Overall Ranking # # # # #
Seq. Equity Change -5.48 % -18.33 % -4.42 % -3.51 % 0.82 %
Seq. Long Term Debt Change 0 % - - - -



Long Term Debt to Equity third quarter 2022 Comment
In Spite of the long-term debt repayement of 0%, in III. Quarter ,Long Term Debt to Equity detoriated to 0.14, above company's average Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry Kempharm Inc achieved lowest Long Term Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
Learn more about KMPH
Long Term Debt to Equity Ratio KMPH on the trailing twelve month basis
Long Term Debt to Equity third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Kempharm Inc's Equity $ 94 Millions Visit KMPH's Balance sheet
Kempharm Inc's Long Term Debt $ 13 Millions Visit KMPH's Balance sheet
Source of KMPH's Sales Visit KMPH's Sales by Geography


Cumulative Kempharm Inc's Long Term Debt to Equity

KMPH's Long Term Debt to Equity for the trailling 12 Months

KMPH Long Term Debt to Equity

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth -28.8 % -24.05 % 44.21 % - -
Y / Y Long Term Debt TTM Growth - - - - -
Long Term Debt to Equity TTM 0.06 0.03 - 0 0.24
Total Ranking TTM # # # # #
Seq. Equity TTM Growth -5.48 % -18.33 % -4.42 % -3.51 % 0.82 %
Seq. Long Term Debt TTM Growth 0 % - - - -


TTM Long Term Debt to Equity Comment
On the trailing twelve months basis Despite of the long-term debt repayement of 0% in III. Quarter, Long Term Debt to Equity improved to 0.06, above Kempharm Inc's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry KMPH recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. 0.

Explain Long Term Debt to Equity Ratio?
Learn more about KMPH
Long Term Debt to Equity Ratio KMPH on the trailing twelve month basis

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market # 0


TTM Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Long Term Debt to Equity in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Long Term Debt to EquitySep 30 2022 MRQ Long Term DebtSep 30 2022 MRQ Equity
Geron Corp  0.35 $ 37.799  Millions$ 108.172  Millions
Metacrine Inc   0.34 $ 12.580  Millions$ 37.065  Millions
Syros Pharmaceuticals Inc   0.31 $ 40.514  Millions$ 129.171  Millions
Medavail Holdings Inc   0.31 $ 9.751  Millions$ 31.306  Millions
Sigilon Therapeutics Inc   0.31 $ 13.621  Millions$ 44.410  Millions
Apellis Pharmaceuticals Inc   0.30 $ 92.663  Millions$ 307.416  Millions
Iterum Therapeutics Plc  0.29 $ 9.298  Millions$ 32.549  Millions
Alkermes Plc   0.28 $ 290.904  Millions$ 1,042.854  Millions
Mersana Therapeutics inc   0.28 $ 24.853  Millions$ 90.229  Millions
Organogenesis Holdings Inc   0.26 $ 67.600  Millions$ 256.328  Millions
Gossamer Bio Inc   0.26 $ 14.834  Millions$ 56.351  Millions
Rhythm Pharmaceuticals inc   0.26 $ 72.961  Millions$ 281.195  Millions
Aytu Biopharma inc   0.25 $ 13.560  Millions$ 53.906  Millions
Roivant Sciences Ltd   0.25 $ 376.058  Millions$ 1,514.149  Millions
Uniqure N v   0.24 $ 102.394  Millions$ 421.170  Millions
Oncorus Inc   0.24 $ 19.257  Millions$ 79.996  Millions
Selecta Biosciences Inc  0.24 $ 20.215  Millions$ 84.907  Millions
Biomarin Pharmaceutical Inc  0.24 $ 1,082.033  Millions$ 4,568.514  Millions
Blueprint Medicines Corporation  0.22 $ 143.539  Millions$ 640.307  Millions
Savara Inc   0.22 $ 26.010  Millions$ 116.514  Millions
Arcturus Therapeutics Holdings Inc   0.22 $ 32.038  Millions$ 145.667  Millions
Capricor Therapeutics inc   0.22 $ 3.376  Millions$ 15.426  Millions
Liquidia Corporation  0.21 $ 19.741  Millions$ 95.034  Millions
Cue Biopharma Inc   0.20 $ 9.956  Millions$ 50.764  Millions
Iveric Bio Inc   0.18 $ 47.649  Millions$ 259.526  Millions
Centessa Pharmaceuticals Plc  0.18 $ 68.200  Millions$ 372.921  Millions
United Therapeutics Corporation  0.18 $ 800.000  Millions$ 4,562.200  Millions
Orgenesis Inc   0.17 $ 5.162  Millions$ 30.250  Millions
Lexicon Pharmaceuticals Inc   0.17 $ 23.784  Millions$ 144.018  Millions
Equillium Inc   0.16 $ 4.616  Millions$ 28.160  Millions

Date modified: 2022-11-12T19:26:45+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

UUU's Profile

Stock Price

UUU's Financials

Business Description

Fundamentals

Charts & Quotes

UUU's News

Suppliers

UUU's Competitors

Customers & Markets

Economic Indicators

UUU's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071